Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers
Completed · Phase 1 · Has a placebo group
Conditions studied: Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder, Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)
In brief
Phase 1 single dose study of ALXN1101 in healthy volunteers.
Key facts
- Study ID
- NCT01894165
- Run by
- Origin Biosciences
- People needed
- 24
- Starts
- 2013-06-01
- Expected to finish
- 2013-09-01
- Last updated by the study team
- 2019-03-19
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- Parexel Baltimore EPCU — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.